Executive Committee and Trustees
Dr Renata Walewska, Bournemouth (Chair)
Dr Renata Walewska has been a consultant haematologist at the Royal Bournemouth Hospital since 2010. She qualified in Sheffield and completed her specialist haematology training in Leicester where also she completed a PhD in identifying and characterising novel markers in CLL. She has been an active member of the UK CLL Forum and is part of the writing committee that recently updated the national BSH CLL guidelines, since March 2019 she is chairing UK CLL Forum.
Dr Walewska is an invited clinical advisor to the Evidence Review Group for NICE appraisals. In addition to CLL, she has developed an interest in Splenic Marginal Zone Lymphoma. She is a member of the NCRI CLL Low Grade NHL subgroup and also collaborates internationally with colleagues developing trials in SMZL. She remains active in scientific research and holds an honorary contract with Southampton University.
Dr Piers Patten, London (Secretary)
Dr Piers Patten, FRCP FRCPath PhD
Clinical Senior Lecturer, King’s College London
Consultant Haematologist King’s College and Guy’s and St Thomas’ Hospitals, London
Dr Piers Patten is Clinical Senior Lecturer at King’s College London (KCL) and Consultant Haematologist at King’s Health Partners, incorporating King’s College (KCH) and Guy’s and St Thomas’ Hospitals (GSTT). He qualified from Bristol Univeristy in 1997, and undertook his Haematology training in London between 2000 and 2008. This included his Blood Cancer UK funded Clinical Training Fellowship resulting in a successful PhD investigating the microenvironment of CLL. This work was chosen as the winner of the inaugural CLL Catovsky in 2006.
Between 2009 and 2013, he undertook a Blood Cancer UK-funded Post-Doctoral Visiting Fellowship at the Feinstein Institute of Medical Research, New York, USA. Both periods of research resulted in his long term interest in the CLL/lymphoma tumour microenvironment. He recently obtained an MRC-funded Clinical Academic Research Partnership award, a programme designed to foster ongoing and future cross-seeding of clinical and academic biomedical translational research.
Dr Patten leads the King’s Health Partners CLL service, is Secretary for the UK CLL Forum and is actively involved in the NCRI CLL and low grade clinical studies subgroups. As part of this, he contributes to national and local guidelines and NICE technology appraisals on behalf of the forum. He undertakes an extensive clinical research portfolio in CLL/lymphoma trials at KHP which run alongside his laboratory research at KCL (https://kclpure.kcl.ac.uk/portal/en/persons/piers-patten(a8eb971c-0d00-45be-b66c-399f2d56d40e).html). In addition, he is highly engaged with and committed to training and education for students, trainees, allied health professionals, fellow consultants, scientists and patients at local, regional and national level.
Dr Nilima Parry-Jones, Abergavenny (Treasurer)
Dr Nilima Parry-Jones is a Consultant Haematologist at Aneurin Bevan University Health Board, where she subspecialises in Lymphoma and CLL. She graduated in Medicine from University College, London in 1992, and completed specialist haematology training in London, completing her MD thesis on mantle cell lymphoma presenting with leukaemia at the Institute of Cancer Research/Royal Marsden. She is the chair of the haemato-oncology guidelines taskforce of the British Society for Haematology, and current treasurer of UK CLL Forum.
Professor Jonathan Strefford, Southampton
As a Professor of Cancer Genomics, and an Honorary NHS Clinical Scientist, my research is translational and spans genomic screening, diagnostic methods as well as molecular mechanisms. My focus is on the application of massively parallel sequencing approaches to dissect the human genome and its epigenetic regulation. We then exploit these findings to develop novel biomarkers that help predict the disease course in cancer patients.
My research focuses on the study of a number of mature B-cell neoplasm, in particular chronic lymphocytic leukaemia (CLL) and splenic marginal zone lymphoma (SMZL) and to a lesser extent follicular (FL) and diffuse large b-cell lymphoma (DLBCL).. The research projects coordinated by Professor Strefford runs from biomarker discover, using a plethora of genomics approaches, to biomarker validation employing large international patient cohorts, to functional analysis, employing in vitro and in vivo model systems.
Dr Ingo Ringshausen, Cambridge (Website Co-Ordinator)
Dr John Riches, London (Website Co-Ordinator, Paper of the Month – Clinical)
Dr John Riches is a consultant haemato-oncologist at Barts Health NHS Trust in London specialising in CLL and lymphoma. He studied medicine at Oxford University and undertook haematology training at Imperial College, London, becoming a fellow of the Royal College of Pathologists in 2015. He is also a Senior Lecturer at Barts Cancer Institute where he leads a research group investigating CLL and lymphoma metabolism
Dr Sunil Iyengar, London (NICE/NHS England)
Dr Sunil Iyengar is a consultant haematologist working at Royal Marsden Hospital and Institute of Cancer Research. He qualified at Bangalore Medical College and University in 2001 before undertaking haematology training at University College Hospital London, being awarded FRCPath in 2009. Dr Iyengar was awarded a PhD based on research into PI3 kinase signalling in Mantle cell lymphoma and won the Royal College of Pathologists medal for research in 2014. He was appointed as a Consultant Haematologist and honorary lecturer in 2014. He is a member of the UK NCRI CLL subgroup and lead for rare leukaemias.
Dr Toby Eyre, Oxford (Twitter)
Dr Toby Eyre is a consultant haematologist at Oxford University Hospitals NHS Foundation Trust specialising in the management of lymphoid malignancies. He trained at the University of Bristol and qualified in 2006 before undertaking Haematology training in Oxford and being awared FRCPath in 2016. He has completed an MD Doctorate Thesis in early phase trials and biomarker studies in aggressive lymphoid disease in 2017. He completed his haematology training in the Oxford deanery between 2010 and 2017. He is an investigator on a number of national UK lymphoma and chronic lymphocytic leukaemia trials and has published over 80 peer-review articles on areas of lymphoma and CLL and has presented regularly at national and international conferences.
He is a core member of the low grade lymphoma and elderly high grade lymphoma NCRI clinical studies group and a member of the BSCH guideline writing groups for various lymphoid subtypes. He is a member of the BSH Haemato-Oncology Task Force.
He also has a strong interest in teaching and training and has completed a post-graduate Diploma in Medical Education.
Professor Tanja Stankovic, Birmingham (Paper of the Month – Scientific)
Professor Tatjana Stankovic is a Professor in Cancer Genetics.
Professor Tatjana Stankovic has published over 90 research papers in high impact scientific journals as well as reviews in the fields of cancer genetics and DNA damage response. She has received grants from the Bloodwise (previously Leukaemia Research Fund, Cancer Research UK, Kay Kendall Leukaemia Fund, and CLIC.
She is an enthusiastic advocator of translational cancer research and gives frequent talks at both national and international meetings.
Mrs Lianne Palmer, Oxford (Nurse Liaison)
Ms Helen Knight, Nottingham (Nurse Liaison)
Professor Anna Schuh, Oxford (Senior Advisory Group)
Current Role: Professor Anna Schuh, MD, PhD, FRCP, FRCPath, was appointed as the Director for Molecular Diagnostics, Department of Oncology, University of Oxford in 2014. She has been the Clinical Lead for the Oxford Molecular Diagnostics Centre (OMDC) since 2008. She is a honorary consultant haematologist and the Director of the University’s online part-time Master’s Programme in Precision Cancer Medicine.
Clinical Focus & Interest: Prof. Schuh is interested in chronic lymphocytic leukaemia (CLL) and is the Chief Investigator of Oxplored, a programme aimed at improving risk prediction of patients with pre-B cell malignancies. She has served as a principal or chief investigator in over 50 early and late phase clinical trials in CLL and has authored or co-authored over 260 publications.
Experience: Prof. Schuh was the Clinical Lead for the Oxford Genomics Medicine Centre from 2014 to 2017 and leads the Genomics England Clinical Interpretation Partnership for Haematological Malignancies. In addition to other national and international roles, she also chaired the UK CLL Forum from 2016 to 2019 which promotes training and education, and she led the UK’s guidelines writing group for CLL Therapy on behalf of the British Society of Haematology.
Affiliations: Prof. Schuh was recently appointed as the Chair of CLL Research in the UK by the National Cancer Research Institute and to the board of the international workshop on CLL (iwCLL). She is a visiting faculty member of the Muhimbili University with Health and Allied Sciences in Dar es salaam, Tanzania and the Chief Investigator of an NIHR funded Global Health Programme that aims to improve early diagnosis of EBV-related lymphomas in East Africa.
Professor Adrian Bloor, Manchester (NICE/NHS England)
Professor Adrian Bloor MA MB BChir PhD FRCP FRCPath
Adrian trained in Haematology at Cambridge University and University College Hospital in London before moving to Manchester in 2006 to take up a Consultant post in Haemato-Oncology. He has a special interest in the management of Lymphoid Malignancies (CLL and Lymphoma), Cellular Therapies, Stem Cell Transplantation and in Clinical Trials and is a Director of the Christie Stem Cell Transplant Program. He is Principle or Chief Investigator for a large number of trials in Haemato-Oncology and Stem Cell Transplantation and is a member of the NCRI CLL Clinical Trials Committee, the Blood and Stem Cell Transplantation Clinical Reference Group (NHS England) the Leeds CLL Trials Management Group, the UK CLL Forum Executive Committee and Medical Advisory Panels to the Lymphoma Association and Bloodwise.
Professor Peter Hillmen, Leeds (Senior Advisory Group)
Dr Andrea Pepper, Brighton (Charity Commission)
Andrea is a Reader and laboratory-based research scientist who runs the leukaemia and lymphoma research team at Brighton and Sussex Medical School (BSMS) alongside her husband Prof. Chris Pepper and Dr Simon Mitchell. She originally trained as a Biomedical scientist at St. Thomas’s hospital in London and then at King’s College Hospital. In 1996 she moved to King’s College London University as a research scientist and completed her PhD on AML in 1999. Since then she has worked predominately on CLL but also follicular lymphoma and lately, AML again. In 2017 she moved to BSMS where the research team is rapidly expanding following grant awards from the MRC, Blood cancer UK, Sussex Cancer Fund, UKRI and Leukaemia UK. She works closely with fellow executive committee member Dr. Roz Johnston.
Professor Andrew Pettitt, Liverpool (Senior Advisory Group)
Professor Andrew Pettitt studied Medicine at the University of Cambridge (1983-1989) before taking up clinical training posts in Internal Medicine (Nottingham, 1990-1992) and Haematology (Liverpool, 1992-2000), during which time he completed a PhD on drug resistance in chronic lymphocytic leukaemia (CLL).
In 2000, he was appointed as Clinical Senior Lecturer in Haematology at the University of Liverpool, with subsequent promotion to Reader (2004), Personal Chair (2006) and Ronald Finn Professor of Experimental Medicine (2013). University leadership roles include Head of Department of Molecular and Clinical Cancer Medicine (2011-2020) and Chair of the Clinical Trials Oversight Committee (from 2018).
Andrew is an Honorary Consultant Haemato-oncologist and Associate Medical Director (from 2020) at The Clatterbridge Cancer Centre NHS Foundation Trust, as well as Director of the Liverpool Health Partners Cancer Programme (from 2019) and inaugural Director of the Liverpool Cancer Research Institute.
At national level, Andrew is Chair of the National Cancer Research Institute (NCRI) Lymphoma Research Group (from 2017), having previously chaired the NCRI Haematological Oncology Clinical Studies Group (2012-2017) and UK CLL Forum (2006-2012). He also represents the UK in the European Lymphoma Institute (from 2019).
Dr Ben Kennedy, Leicester (Real World Data)
Dr Helen McCarthy, Bournemouth (Real World Data, Pharma Liaison)
Dr Helen Marr, Newcastle
Dr Helen Marr is a Consultant Haematologist working at the Freeman Hospital in Newcastle upon Tyne. She trained at the University of Nottingham and qualified in 2002. She worked as a haematology registrar in Christchurch, New Zealand from 2006 to 2008 before going on to complete her specialty haematology training in the Northern Deanery in 2016. She was awarded her FRCPath in 2012 and was awarded a PhD into the role of CD38 in IRF4 transcription in CLL in 2015. Having completed her specialty training, Dr Marr worked as a Trials Fellow at the Freeman Hospital for 18 months, as a sub investigator on early and late phase malignant haematology trials. She was appointed as a Consultant in December 2017. She is the Chair of the Regional North of Tyne Haematology MDT.
Mr Marc Auckland (Chair of the CLL Support Association)
I am a Masters in Business Administration and a Fellow of the CIPD. I have worked nationally and globally in Telecommunications, Transport and Health. I have advised both Labour and Conservatives on Leadership and education. I led the development of a report presented to the European Council of Ministers working on recommendations on the future of education and skills. My work has featured in the Institute of Directors, Times and Wall Street Journal. I feature in the University of Warwick Case studies and won the Times Business in the Community award. I have presented to Government Ministers, Multi National Companies and Business schools at Global conferences on Leadership and Knowledge Management. A qualified leadership Talent Coach and mentor. Now Chair of CLL Support, the patient arm of the CLL Forum. https://www.cllsupport.org.uk/
Dr Alison Michie, Glasgow (Joint Scientific Secretary)
Dr Alison M. Michie
Reader in Molecular Lymphopoiesis, Institute of Cancer Sciences, University of Glasgow.
Alison graduated with a PhD in Biochemistry from the University of Glasgow, before being awarded a post-doctoral fellowship from Cancer Research Institute to study at the University of Toronto. The award of an MRC Career Development Award enabled Alison to return to the University of Glasgow to start her independent research group investigating the molecular events that regulate lymphocyte lineage commitment and development. During the course of her studies Alison established that subversion of PKC signalling acts as an oncogenic trigger in B lymphocytes, resulting in the development of CLL in vitro and in vivo. This finding resulted in a change in focus for her research group from lymphocyte development towards translational CLL research and in 2005, Alison established the Molecular Lymphopoiesis group within Institute of Cancer Sciences. The main focus of Alison’s research is to determine the cellular and molecular mechanisms that underlie the initiation and progression of CLL, with a view to identifying novel targets for therapeutic intervention: the CLL-like mouse model offers great potential for translational research, resembling a model of progressive CLL which, combined with studies involving CLL patient samples, provides a cohesive translational platform to enable characterisation of novel targets/therapies.
Dr Alan Ramsay, London (Joint Scientific Secretary/Facebook)
Dr. Alan G. Ramsay is a Senior PI at King’s College London leading a research group (Lymphoma Immunology) focusing on translational research. His work has characterized tumour cell-induced T cell immune evasion mechanisms in CLL/lymphoma and translated bench science to clinical trials with immunotherapy. Current projects are modeling and studying immunosuppressive tumour microenvironment (TME) stromal cells in order to gain knowledge for optimising future immunotherapy-based treatments for patients. Previous Fellowships have included a European Hematology Association (EHA) grant at Barts Cancer Institute and a British Society of Haematology (BSH) award at King’s.
Professor Ulf Klein, Leeds (Joint Scientific Secretary)
Dr Klein is Professor of Immunology and Haemato-oncology at the Leeds Institute of Medical Research at St. James’s, School of Medicine, University of Leeds. He has been working on the molecular basis of B-cell development and lymphomagenesis throughout his career. He obtained his PhD at the University of Cologne in 1998, before moving to Columbia University, New York, for postdoctoral research. In 2009, he established his own lab at Columbia University, where he was promoted to Associate Professor with tenure in 2016. Dr Klein joined the University of Leeds in 2017, where he continues his work on elucidating the oncogenic mechanisms that cause malignant transformation of B cells. https://medicinehealth.leeds.ac.uk/medicine/staff/517/professor-ulf-klein
Dr Feargal McNicholl, Northern Ireland
Dr Alison McCaig, Glasgow
Dr Alison McCaig is a consultant haematologist at the Queen Elizabeth University Hospital, Glasgow, where she has a specialist interest in chronic lymphocytic leukaemia and lymphoma. She trained at the University of Edinburgh Medical School and qualified in 2000, before undertaking haematology training in the West of Scotland, being awarded FRCPath in 2011. During her Haematology specialist training, Dr McCaig completed a PhD research programme investigating novel therapeutic approaches for chronic lymphocytic leukaemia, at the Paul O’Gorman Leukaemia Research Laboratory, University of Glasgow. In her clinical practice, Dr McCaig has been a local principal investigator for several CLL clinical trials in addition to maintaining her academic interests.
Dr Helen Parry, Birmingham (Real World Data/NICE)
Dr Helen Parry completed her undergraduate training with honours at the University of Birmingham. She was awarded an MSc (Dist) in 2005 and subsequently in 2016 completed a Wellcome PhD fellowship researching viral responses and secondary immunodeficiency in patients with CLL. During her PhD she spent time at Mayo Clinic, studying the role of cytomegalovirus in CLL. Since 2016, she has been an NIHR clinical lecturer in Haematology at the University of Birmingham and Queen Elizabeth Hospital, Birmingham. Her main areas of research are secondary immunodeficiency, T cell immunity and vaccine responsiveness in patients with haematological malignancies. She is also interested in medical education and public engagement and is co-founder of Blooducation podcasts.
Dr Nicolas Martinez-Calle, Nottingham (Real World Data/NICE)
Nicolas Martinez-Calle, MD, MSc, PhD(c), is currently a consultant Haematologist in Nottingham University Hospitals NHS Trust with a special interest in CLL and lymphoma. Dr. Martinez-Calle completed his medical degree in Colombia at La Sabana University in 2008 and his specialty training in Spain at the Navarra University Clinic in 2015. He is currently completing his PhD studies at Navarra University in the field of epigenetics and DNA methylation. He was granted the Celgene-SEHH (Spanish Society of Haematology) scholarship in 2015 for completion of his PhD work.
Dr. Martinez-Calle was an Honorary Clinical Assistant Professor at Navarra University school of Medicine from 2014-2016 and has prior experience working in pharmaceutical industry as a new product medical advisor during 2008-2009. He is an active member of the European Haematology Association and the British Society of Haematology.
Dr. Martinez-Calle main research interest is CLL. He has been Sub-Investigator of more than 30 clinical trials in lymphoma and CLL and currently principal investigator of 3 studies currently recruiting in Nottingham in both CLL and lymphoma. He has authored or co-authored over 25 relevant publications in the field.
Mr Nick York (Co-Opted Member – Leukaemia Care)
A diagnosis of CLL in 2009 inspired me to work as a patient advocate to build on the work of those who had gone before and continue to bring patients and other stakeholders together to improve outcomes for those affected by a diagnosis of CLL. A previous trustee of CLL Support and founder administrator of UK and international on-line support communities; I work today as Patient Advocacy Healthcare Liaison Officer with Leukaemia Care https://www.leukaemiacare.org.uk and am founder and Chair of the CLL Advocate Network the international coalition of CLL support organisations https://www.clladvocates.net
Prof George Follows (Senior Advisory Group)
George Follows received his medical degree from Oxford University Medical School, UK, and completed his medical and hematology training in Newcastle and Edinburgh, and his PhD at Leeds University, UK. He moved to Cambridge University as a Leukaemia Research Fund Senior Clinical Fellow and was later appointed Clinical Lead for lymphoma, CLL and clinical trials. He is a former chair of the UK CLL Forum and CLL Guidelines Panel and currently chairs the BCSH UK Hodgkin Lymphoma Guidelines Panel. Dr Follows is the the Research Lead for hematology clinical trials at the Cambridge Cancer Trials Centre and was recently appointed to the academic faculty of the Anglia Ruskin Medical School as the Visiting Professor of Haematology. He has authored/co-authored over 90 peer-reviewed papers in different areas of hematological biology and therapeutics in journals, including the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Cell, and Nature Genetics.